Danaher Corp
DHRQ4 2024(DHR Q3 FY2024)Estimated1% AI
AI Revenue %
1%
AI Fair Value
$759.1M
AI Revenue (Q)
$174.8M
Total Revenue (Q)
$17.5B
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Q3 FY2024 (three-month period ended September 27, 2024). Total sales $5,798M. Segments: Biotechnology $1,653M, Life Sciences $1,782M, Diagnostics $2,363M. No AI revenue disclosure. The Life Sciences segment took a $222M intangible asset impairment related to softness in the genomics market, indicating challenges in one of the more AI-adjacent areas. No AI-specific revenue mentioned. Conservative 1% estimate. Math: ~$58M estimated / $5,798M total = ~1.0%.
Analyzed by claude-opus-4-6
Quoted Figures
Sales $5,798 [three-month period ended September 27, 2024]
10-Q Q3 FY2024, Consolidated Condensed Statements of Earnings
Biotechnology $1,653; Life Sciences $1,782; Diagnostics $2,363 [three-month period ended September 27, 2024]
10-Q Q3 FY2024, Note 6 Segment Information
During the third quarter of 2024, the Company concluded that it had an impairment indicator for an indefinite-lived trade name within the genomics consumable business included in the Life Sciences segment
10-Q Q3 FY2024, Note 9 Goodwill and Other Intangible Assets
AI Products Identified (Ring 1)
Embedded instrument algorithms (digital pathology, flow cytometry, clinical chemistry)
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Biotechnology consumables/bioprocessingLife Sciences instrumentsDiagnostics instruments
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix